The activity of alemtuzumab is independent of P53 mutational status in fludarabine refractory CLL:: Final analysis from the CLL2H study of the GCLLSG

被引：0
|
作者：
Zenz, T. [2 ]
Haebe, S. [2 ]
Denzel, T. [2 ]
Winkler, D. [2 ]
Hallek, M. [1 ]
Hensel, M. [3 ]
Lengfelder, E. [4 ]
Dreger, P. [3 ]
Jaeger, U. [5 ]
Doehner, H. [2 ]
Stilgenbauer, S. [2 ]
机构：
[1] Univ Cologne, Dept Internal Med, Cologne, Germany
[2] Univ Ulm, Ulm, Germany
[3] Univ Heidelberg, Heidelberg, Germany
[4] Univ Mannheim, Mannheim, Germany
[5] Univ Vienna, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：193 / 194
页数：2
相关论文
共 21 条
  • [1] The activity of alemtuzumab is independent of p53 mutational status in fludarabine refractory CLL:: Interim analysis from the CLL2H study of the GCLLSG
    Zenz, T.
    Haebe, S.
    Denzel, T.
    Winkler, D.
    Kroeber, A.
    Kienle, D.
    Hallek, M.
    Hensel, M.
    Lengfelder, E.
    Truemper, L.
    Dreger, P.
    Jaeger, U.
    Doehner, H.
    Stilgenbauer, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 42 - 42
  • [2] Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H trial of the GCLLSG)
    Stilgenbauer, Stephan
    Winkler, Dirk
    Buehler, Andreas
    Zenz, Thorsten
    Groner, Sija
    Busch, Raymonde
    Hensel, Manfred
    Duehrsen, Uhich
    Finke, Juergen
    Dreger, Peter
    Jaeger, Ulrich
    Lengfelder, Eva
    Truemper, Lorenz
    Soeling, Ulrike
    Schlag, Rudolf
    Hallek, Michael
    Doehner, Hartmut
    BLOOD, 2007, 110 (11) : 918A - 918A
  • [3] Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers
    Stilgenbauer, Stephan
    Zenz, Thorsten
    Winkler, Dirk
    Buehler, Andreas
    Groner, Sija
    Busch, Raymonde
    Hensel, Manfred
    Duehrsen, Ulrich
    Finke, Juergen
    Dreger, Peter
    Jaeger, Ulrich
    Lengfelder, Eva
    Truemper, Lorenz H.
    Soeling, Ulrike
    Schlag, Rudolf
    Hallek, Michael
    Doehner, Hartmut
    BLOOD, 2008, 112 (11) : 127 - 127
  • [4] Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).
    Stilgenbauer, S
    Winkler, D
    Kröber, A
    Kienle, D
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    BLOOD, 2004, 104 (11) : 140A - 140A
  • [5] Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL:: CLL2H study of the German CLL Study Group (GCLLSG)
    Stilgenbauer, S
    Kröber, A
    Winkler, D
    Kienle, D
    Busch, R
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    ANNALS OF ONCOLOGY, 2005, 16 : 43 - 43
  • [6] P53 independent activity of subcutaneous MabCampath® in fludarabine-refractory CLL
    Stilgenbauer, S
    ANNALS OF ONCOLOGY, 2005, 16 : 256 - 256
  • [7] High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial
    Bloehdorn, Johannes
    Sill, Martin
    Langer, Christian
    Benner, Axel
    Zenz, Thorsten
    Buehler, Andreas
    Busch, Raymonde
    Dreger, Peter
    Jaeger, Ulrich
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2013, 122 (21)
  • [8] NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg
    Schnaiter, Andrea
    Rossi, Marianna
    Paschka, Peter
    Cazzola, Mario
    Doehner, Konstanze
    Edelmann, Jennifer
    Buehler, Andreas
    Kless, Sabrina
    Mertens, Daniel
    Busch, Raymonde
    Mack, Silja
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2012, 120 (21)
  • [9] NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG
    Schnaiter, Andrea
    Paschka, Peter
    Rossi, Marianna
    Zenz, Thorsten
    Buehler, Andreas
    Winkler, Dirk
    Cazzola, Mario
    Doehner, Konstanze
    Edelmann, Jennifer
    Mertens, Daniel
    Kless, Sabrina
    Mack, Silja
    Busch, Raymonde
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2013, 122 (07) : 1266 - 1270
  • [10] Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.
    Bloehdorn, Johannes
    Sill, Martin
    Buehler, Andreas
    Mack, Silja
    Winter, Doris
    Bullinger, Lars
    Rouhi, Arefeh
    Kuchenbauer, Florian
    Mertens, Daniel
    Benner, Axel
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2012, 120 (21)
123